Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (96)

IV-01Federico Amato

Explainable Machine Learning prediction of edema adverse events in NSCLC patients treated with tepotinib

Thursday 15:25-16:55

IV-02Enrique José Bandín Vilar

Population pharmacokinetics of aripiprazole and its active metabolite dehydroaripiprazole in subjects receiving once-monthly intramuscular aripiprazole.

Thursday 15:25-16:55

IV-03Bruna Bernar Dias

PK/PD modelling of the effect of nanoencapsulated quetiapine on cortical dopamine concentrations in schizophrenia phenotyped rats

Thursday 15:25-16:55

IV-04Divakar Budda

Mu-opioid receptor binding of morphine and its main metabolites: impact of non-linear BBB transport of morphine.

Thursday 15:25-16:55

IV-05Chao Chen

Model-based meta-analysis of aggregate data on Parkinson’s disease clinical scores to inform future trial design

Thursday 15:25-16:55

IV-06Lu Chen

Posaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race

Thursday 15:25-16:55

IV-07Alexandre Duong

NONMEM versus nlmixr2 : An example of external evaluation of gentamicin Pop-PK models

Thursday 15:25-16:55

IV-08Emma Eckernäs

Optimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer model

Thursday 15:25-16:55

IV-09Mehdi El Hassani

Does sample size, sampling strategy, or handling of concentrations below the lower limit of quantification matter when externally evaluating population pharmacokinetic models?

Thursday 15:25-16:55

IV-10Selma El Messaoudi

Evaluation in model averaging: an application to viral dynamic models

Thursday 15:25-16:55

IV-11Ibrahim El-Haffaf

Model-informed precision dosing: can the administration method influence the predictive performance of a model? An example with piperacillin.

Thursday 15:25-16:55

IV-12Raphaela Schenk

How to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition

Thursday 15:25-16:55

IV-13Sungwoo Goo

Graph Diffusion Model to Understand Quantitative Systems Pharmacology

Thursday 15:25-16:55

IV-14Farina Hellmann

Population pharmacokinetic modeling of total active moiety exposure following doses of TV 46000, a long-acting subcutaneous risperidone injection

Thursday 15:25-16:55

IV-15Niels Hendrickx

Predicting individual disease progression including parameter uncertainty in rare neurodegenerative diseases: the example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS)

Thursday 15:25-16:55

IV-16Jina Kim

Proteolysis-Targeting Chimera (PROTAC) Design using Integrated Artificial Intelligence (AI) and Quantitative Systems Pharmacology (QSP) Model.

Thursday 15:25-16:55

IV-17Jane Knöchel

Using semi-mechanistic modelling to inform the design of the Ph3 program for a novel PCSK9 antisense oligonucleotide

Thursday 15:25-16:55

IV-18Julia Korell

Population Pharmacokinetic Model for BI 1015550 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Thursday 15:25-16:55

IV-19Ryuji Kubota

Developing SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer

Thursday 15:25-16:55

IV-20Shaun Kumar

Empirical Population Pharmacodynamic Models for beti-cel for the Treatment of Patients with β-Thalassemia who Require Regular Transfusions.

Thursday 15:25-16:55

IV-21Minji Kwon

Optimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches

Thursday 15:25-16:55

IV-22Mun Kyungran

Development of User-Friendly Bayesian Predictive Platform for Blood Boron-10 Pharmacokinetics following Intravenous Infusion of [10B] L-4-BORONOPHENYLALANINE

Thursday 15:25-16:55

IV-23Jennifer Lang

Development of a semi-mechanistic pharmacokinetic/pharmacodynamic model of a small interfering RNA targeting liver proteins in mice and cynomolgus monkeys

Thursday 15:25-16:55

IV-24Silvia Maria Lavezzi

Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study

Thursday 15:25-16:55

IV-25Albin Leding

Population pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites

Thursday 15:25-16:55

IV-26Hyunjung Lee

External validation of population pharmacokinetic models on 7 published models of moxifloxacin-treated tuberculosis patients

Thursday 15:25-16:55

IV-27Moon Hee Lee

First-in-Human Dose Selection for TU7710 through Pharmacokinetic and Pharmacodynamic Modeling and Simulation

Thursday 15:25-16:55

IV-28Giulia Lestini

Population pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria

Thursday 15:25-16:55

IV-29Letao Li

Preeclampsia increases maternal exposure to betamethasone in pregnancy: a population pharmacokinetic study

Thursday 15:25-16:55

IV-30Letao Li

Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role?

Thursday 15:25-16:55

IV-31Hyeong-Seok Lim

Translational pharmacokinetic-pharmacodynamic modeling and simulation to predict efficacious human doses for YH35324 (GI-301)

Thursday 15:25-16:55

IV-32Klaus Lindauer

Allometric Scaling for Efficacious First-in-Human Dose Prediction of Pharmacologically-Active Parent and Metabolite Based on Rat, Dog and Monkey PK data

Thursday 15:25-16:55

IV-33Carolina Llanos-Paez

Extended model-based meta-analysis of joint longitudinal FEV1 and exacerbation rate in randomized COPD trials

Thursday 15:25-16:55

IV-34Jos Lommerse

Building Effective Visualizations to Assess and Communicate Fit for Pharmacometric Models with Covariates (VACHETTE)

Thursday 15:25-16:55

IV-35Servane Lunven

Generative Models for Synthetic Data Generation: Application to PKPD data

Thursday 15:25-16:55

IV-36Julia Macente

Physiologically-based Pharmacokinetics modelling to predict the systemic exposure of medicines in infants via breastmilk: a contribution from the ConcePTION Project.

Thursday 15:25-16:55

IV-37Wen Yao Mak

Population pharmacokinetics and pharmacodynamics of eravacycline against pulmonary infections

Thursday 15:25-16:55

IV-38Eleonora Marostica

Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients

Thursday 15:25-16:55

IV-39Sebastian Micluța-Câmpeanu

Automatic model discovery in Quantitative Systems Biology

Thursday 15:25-16:55

IV-40Yersultan Mirasbekov

Characterizing Bootstrap Model Selection Variability Through an Automated Model Building Approach

Thursday 15:25-16:55

IV-41Laurynas Mockeliunas

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Thursday 15:25-16:55

IV-42Felix Müller

Identification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study.

Thursday 15:25-16:55

IV-43Nina Nauwelaerts

Physiologically Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to medicines: a contribution from the ConcePTION Project

Thursday 15:25-16:55

IV-45Jacinta Nwogu

Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites

Thursday 15:25-16:55

IV-46Amaury O'Jeanson

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration?

Thursday 15:25-16:55

IV-47Marije Otto

Evaluation of Darigabat QTc Prolongation in Healthy Volunteers: a Concentration-QTcF Analysis

Thursday 15:25-16:55

IV-48Agustos Cetin Ozbey

Physiologically based pharmacokinetic modelling of the impact of hepatic impairment on glucuronidation – a case study with midazolam.

Thursday 15:25-16:55

IV-49Seongwon Park

Evidence-based evaluation for race difference of pirfenidone using population pharmacokinetics model

IV-50Suemin Park

Exposure-Response Analysis Using Time to Event Data for Bevacizumab Biosimilar, SB8 and the Reference Bevacizumab

Thursday 15:25-16:55

IV-51Elena Pascual García

Towards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth.

Thursday 15:25-16:55

IV-52Blaise Pasquiers

Rituximab in Anti‑Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: population pharmacokinetic modeling and simulations of alternative doses in under-exposed patients

Thursday 15:25-16:55

IV-53Christoph Pfaffendorf

A combined population pharmacokinetic model of proguanil and its active metabolite cycloguanil in infants to adults with uncomplicated malaria

Thursday 15:25-16:55

IV-54Anh Duc Pham

Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa

Thursday 15:25-16:55

IV-55Thao- Nguyen Pham

Effect brain irradiation with X-ray/Proton beam on circulating immune cell in rodents: A longitudinal modeling approach

Thursday 15:25-16:55

IV-56Morgane PHILIPP

Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis

Thursday 15:25-16:55

IV-57Veshni Pillay-Fuentes Lorente

Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites

Thursday 15:25-16:55

IV-58Tim Preijers

Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study

Thursday 15:25-16:55

IV-59Fatiha Rachedi

Predicting Motor function scores using uHex4 biomarker effect in Pompe disease

Thursday 15:25-16:55

IV-60Christopher Rackauckas

Robust Parameter Estimation of Rational Ordinary Differential Equations for NLME and QSP

Thursday 15:25-16:55

IV-61Christopher Rackauckas

Uncertainty quantified discovery of chemical reaction systems via Bayesian scientific machine learning

Thursday 15:25-16:55

IV-62Ibtissem Rebai

Evaluation of the Boruta Machine Learning Algorithm for Covariate Selection

Thursday 15:25-16:55

IV-63Juan Eduardo Resendiz Galvan

Pharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis.

Thursday 15:25-16:55

IV-64Gledys Reynaldo Fernandez

Enlightenment the strategic selection of pegylated rHuEPO candidates using a mechanistic model- driven extrapolation approach of the pharmacokinetics and pharmacodynamics.

Thursday 15:25-16:55

IV-65Karine Rodriguez-Fernandez

Individualized dosing regimen optimization using a population pharmacokinetic-pharmacodynamic model for secukinumab in clinical practice psoriatic patients

Thursday 15:25-16:55

IV-67Soroush Safaei

Developing a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates

Thursday 15:25-16:55

IV-68Medhat M. Said

Disease-drug-drug interaction in drug repurposing of intravenous imatinib for COVID-19 ARDS

Thursday 15:25-16:55

IV-69Eric Salgado

Target engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS)

Thursday 15:25-16:55

IV-70Louis Sandra

Development of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies

Thursday 15:25-16:55

IV-71Darlene Santiago

External Validation of Population PK and PD Models for Characterizing the Impact of CYP2C9 and VKORC1 Genotypes in the Management of Warfarin Therapy in Caribbean Hispanic Patients.

Thursday 15:25-16:55

IV-72Maria Sanz Codina

Evaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling

Thursday 15:25-16:55

IV-73Raphaël Saporta

Translation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments

Thursday 15:25-16:55

IV-74Sebastiaan Sassen

The importance of model selection for a priori model informed precision dosing of vancomycin

Thursday 15:25-16:55

IV-75Sharon Sawe

Population pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis.

Thursday 15:25-16:55

IV-76Stef Schouwenburg

A pooled population pharmacokinetic study of oral and intravenous clavulanic acid in neonates

Thursday 15:25-16:55

IV-77Manna Semere Gebreyesus

Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy

Thursday 15:25-16:55

IV-78Marie Steinacker

Non-linear autoregressive exogenous modelling to predict individual haematotoxicity during chemotherapy

Thursday 15:25-16:55

IV-79Budi Octasari Susanto

Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations

Thursday 15:25-16:55

IV-80Carsten Terjung

Modeling PK and PK/PD in of anti-VEGF agents in a preclinical rabbit model of VEGF-induced retinal hyperpermeability

Thursday 15:25-16:55

IV-81Thi Quyen Tran

Model-based meta-analysis of relationship between pioglitazone and histological outcomes in non-alcoholic steatohepatitis patients

Thursday 15:25-16:55

IV-82Van Thuy Truong

Combining PKPD models with agent-based modelling and reinforcement learning/artificial intelligence algorithm to optimize cancer treatment

Thursday 15:25-16:55

IV-83Pieter Van Brantegem

Longitudinal time to positivity is unable to predict clinical outcome for drug susceptible tuberculosis

Thursday 15:25-16:55

IV-84Marinda van de Kreeke

Interspecies scaling of host inflammatory response during infection

Thursday 15:25-16:55

IV-85Coen van Hasselt

Integrative pharmacokinetic model for esketamine and its metabolite esnorketamine

Thursday 15:25-16:55

IV-86Wisse van Os

Model-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections

Thursday 15:25-16:55

IV-87Sander van Tilburg

Population pharmacokinetics and pharmacodynamics of intravenous immunoglobulin treatment in patients with Guillain-Barré syndrome

Thursday 15:25-16:55

IV-88Peter Velickovic

Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets

Thursday 15:25-16:55

IV-89Diego Vera-Yunca

A translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin

Thursday 15:25-16:55

IV-90Umberto Villani

Model-based rationale for the in vitro characterisation of antimicrobial combinations in Buruli Ulcer

Thursday 15:25-16:55

IV-91Thanakorn Vongjarudech

Optimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis

Thursday 15:25-16:55

IV-92My Luong Vuong

Population pharmacokinetics of fluconazole in critically ill patients: an individual patient data meta-analysis.

Thursday 15:25-16:55

IV-93Zhigang Wang

A repeated time-to-event model linking infliximab clearance to the risk of relapse during maintenance treatment of patients with inflammatory bowel disease

Thursday 15:25-16:55

IV-94Daichi Yamaguchi

Population pharmacokinetic modelling for vancomycin using Bayesian model averaging approach

Thursday 15:25-16:55

IV-95Shuying Yang

Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia

Thursday 15:25-16:55

IV-96Sung-yoon Yang

Prediction of potential drug-drug interaction of tofacitinib and ritonavir using a population modeling approach with allometric scaling method

Thursday 15:25-16:55

IV-97Janice Zhang

Mechanism-based pharmacokinetic-pharmacodynamic modeling of short-term erythroferrone response and long-term efficacy of erythropoietin in chemotherapy-induced anemia rats

Thursday 15:25-16:55

IV-98Qiaolin Zhao

Paracetamol (Acetaminophen) and Metabolites Population Pharmacokinetics Model in children and adults with Spinal Muscular Atrophy

Thursday 15:25-16:55